Bioequivalence Evaluation of Two Cefquinome 2.5% Injectable Products in Piglets
![]() |
Song, In-Bae
(Lab of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chungnam National University)
Kim, Tae-Won (Lab of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chungnam National University) Lee, Hong-Gee (Lab of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chungnam National University) Kim, Myoung-Seok (Jeollanamdo Development Institute for Traditional Korean Medicine) Hwang, Youn-Hwan (Korea Institute of Oriental Medicine) Park, Byung-Kwon (Lab of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chungnam National University) Lim, Jong-Hwan (B&C Biopharm, Advanced Institutes of Convergence Technology) Yun, Hyo-In (Lab of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chungnam National University) |
1 | CVMP. Cefquinome summary report EMEA/MRL/005/95. London: European Agency for the Evaluation of Medicinal Products, 1995. |
2 | Ehinger AM, Schmidt H, Kietzmann M. Tissue distribution of cefquinome after intramammary and "systemic" administration in the isolated perfused bovine udder. Vet J 2006; 172: 147-153. DOI ScienceOn |
3 | El-Gendy AAM, Tohamy MA, Radi AM. Pharmacokinetic profile and some pharmaco- dynamic aspects of cefquinome in chickens. Beni-Suef Vet Med J 2009; 19: 33-37. |
4 | Grahnen A. Design of bioavailability studies. Pharm Int 1984; 5: 100-103. |
5 | Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Therapeut 1990; 28: 72-78. |
6 | Al-Taher AA. Pharmacokinetics of cefquinome in camels. J Anim Vet Adv 2010; 9: 848-852. DOI |
7 | CVMP. Cefquinome (Extension to horses). Summary reprot (3) EMEA/MRL/888/03-FINAL. London: European Agency for the Evaluation of Medicinal Products, 2003. |
8 | Korea Animal, Plant and Fisheries Quarantine and Inspection Agency. In: The guideline of bioequivalence test for veterinary drugs. Korea: 2011; No. 2011-12. |
9 | Korea Animal, Plant and Fisheries Quarantine and Inspection Agency. In: The guideline of residue test for veterinary drugs. Korea: 2011; No. 2011-16. |
10 | Li XB, Wu WX, Su D, Wang ZJ, Jiang HY, Shen JZ. Pharmacokinetics and bioavailability of cefquinome in healthy piglets. J Vet Pharmacol Ther 2008; 31: 523-527. DOI ScienceOn |
11 | Limbert M, Isert D, Klesel N, Markus A, Seeger K, Seibert G, Schrinner E. Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 1991; 35: 14-19. DOI ScienceOn |
12 | Lui B, Zhang C, Zhang X, Yang S, Yu J, Sun J, Lui Y. Pharmacokinetics and bioavailability of cefquinome in crossbred wild boars. J Vet Pharmacol Therap 2012; doi:10.1111/j.1365-2885.2011.01360.x. |
13 | Rose M, Thomas V, Nordmann P. In vitro activity of third and fourth generation cephalosporins against E. coli strains expressing plasmid-encoded AmpC cephalosporinases. In: Risk Management for the Limitation of Antibiotic Resistance, Scientific Symposium. Federal Office of Consumer Protection and Food Safety, Berlin, Germany, 2004; 15-16. |
14 | Uney K, Altan F, Elmas M. Development and validation of an HPLC method for the determination of cefquinome in sheep plasma and its application to the pharmacokinetic study. Antimicrob Agents Chemother 2010; 55: 854-859. |
15 | Westlake WJ. Bioavailability and bioequivalence of pharmaceutical formulations. In: Biopharmaceutical Statistics for Drug Development, New York: Marcel Dekker. 1988: 329-352. |
16 | Yuan L, Sun J, Wang R, Sun L, Zhu L, Luo X, Fang B, Liu Y. Pharmacokinetics and bioavailability of cefquinome in healthy ducks. Am J Vet Res 2011; 72: 122-126. DOI ScienceOn |
![]() |